Mastocytosis. Review of the literature and description of clinical cases

被引:2
作者
Melikyan, A. L. [1 ]
Subortseva, I. N. [1 ]
Goryacheva, S. R. [1 ]
Kolosheinova, T. I. [1 ]
Vakhrusheva, M. V. [1 ]
Kovrigina, A. M. [1 ]
Sudarikov, A. B. [1 ]
Dvirnyk, V. N. [1 ]
Obukhova, T. N. [1 ]
机构
[1] Minist Hlth Russian Fed, Hematol Res Ctr, Moscow, Russia
关键词
cutaneous mastocytosis; systemic mastocytosis; mast cell leukemia; D816V KIT mutation; imatinib; NEOPLASTIC MAST-CELLS; SYSTEMIC MASTOCYTOSIS; HISTOPATHOLOGICAL ASPECTS; RISK STRATIFICATION; IMATINIB MESYLATE; SPANISH NETWORK; KIT MUTATION; DIAGNOSIS; CRITERIA; THERAPY;
D O I
10.17116/terarkh20148612127-134
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The term mastocytosis (MC) encompasses a group of rare diseases characterized by the tumorous proliferation of clonal mast cells and the infiltration of one or several organs. The clinical picture of MC is extremely diverse from skin lesions that can spontaneously regress to the aggressive disease forms associated with organ dysfunction and short survival. Nowadays, the 2008 WHO classification identifies 7 MC subtypes. The disease is diagnosed on the basis of its clinical manifestations and detection of tumorous mast cell infiltrations via morphological, immunohistochemical, immunophenotypic, genetic, and molecular examinations. Abnormal mast cells are characterized by the atypical morphology and pathological expression of CD25 and CD2 antigens. Enhanced serum tryptase activity is a common sign in all MC subtypes. More than 90% of the patients have D816V KIT mutations in the mast cells. This paper reviews the literature. Three cases are described as a clinical example in patients with different MC subtypes.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 59 条
  • [41] Sandes AF, 2011, J HEMATOP, V4, P123, DOI DOI 10.1007/S12308-011-0097-5#
  • [42] Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes
    Sandes, Alex F.
    Yamamoto, Mihoko
    Matarraz, Sergio
    Chauffaille, Maria de Lourdes L. F.
    Quijano, Sandra
    Lopez, Antonio
    Oguro, Tsutomu
    Kimura, Eliza Y. S.
    Orfao, Alberto
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (06): : 895 - 902
  • [43] Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
    Shah, Neil P.
    Lee, Francis Y.
    Luo, Roger
    Jiang, Yibin
    Donker, Marjolein
    Akin, Cem
    [J]. BLOOD, 2006, 108 (01) : 286 - 291
  • [44] Serum tryptase levels in patients with mastocytosis: Correlation with mast cell burden and implication for defining the category of disease
    Sperr, WR
    Jordan, JH
    Fiegl, M
    Escribano, L
    Bellas, C
    Dirnhofer, S
    Semper, H
    Simonitsch-Klupp, I
    Horny, HP
    Valent, P
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2002, 128 (02) : 136 - 141
  • [45] Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis
    Sperr, WR
    Escribano, L
    Jordan, JH
    Schernthaner, GH
    Kundi, M
    Horny, HP
    Valent, P
    [J]. LEUKEMIA RESEARCH, 2001, 25 (07) : 529 - 536
  • [46] Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation
    Spyridonidis, A
    Thomas, AK
    Bertz, H
    Zeiser, R
    Schmitt-Gräff, A
    Lindemann, A
    Waller, CF
    Finke, J
    [J]. BONE MARROW TRANSPLANTATION, 2004, 34 (06) : 515 - 519
  • [47] An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis
    Teodosio, C.
    Garcia-Montero, A. C.
    Jara-Acevedo, M.
    Alvarez-Twose, I.
    Sanchez-Munoz, L.
    Almeida, J.
    Morgado, J. M.
    Matito, A.
    Escribano, L.
    Orfao, A.
    [J]. LEUKEMIA, 2012, 26 (05) : 951 - 958
  • [48] Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes
    Teodosio, Cristina
    Garcia-Montero, Andres C.
    Jara-Acevedo, Maria
    Sanchez-Munoz, Laura
    Alvarez-Twose, Ivan
    Nunez, Rosa
    Schwartz, Lawrence B.
    Walls, Andrew F.
    Escribano, Luis
    Orfao, Alberto
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (03) : 719 - 726
  • [49] Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
    Ustun, Celalettin
    DeRemer, David L.
    Akin, Cem
    [J]. LEUKEMIA RESEARCH, 2011, 35 (09) : 1143 - 1152
  • [50] Standards and standardization in mastocytosis:: Consensus statements on diagnostics, treatment recommendations and response criteria
    Valent, P.
    Akin, C.
    Escribano, L.
    Foedinger, M.
    Hartmann, K.
    Brockow, K.
    Castells, M.
    Sperr, W. R.
    Kluin-Nelemans, H. C.
    Hamdy, N. A. T.
    Lortholary, O.
    Robyn, J.
    van Doormaal, J.
    Sotlar, K.
    Hauswirth, A. W.
    Arock, M.
    Hermine, O.
    Hellmann, A.
    Triggiani, M.
    Niedoszytko, M.
    Schwartz, L. B.
    Orfao, A.
    Horny, H.-P.
    Metcalfe, D. D.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 (06) : 435 - 453